Navigation Links
Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
Date:8/12/2008

Owing to Well-Established and Effective Insulin-Based Therapies, Market Growth Will be Modest Through 2017, According to a New Report from Decision

Resources

WALTHAM, Mass., Aug. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the most significant driver of growth in the type 1 diabetes market will be the shift in the standard of care away from regular human insulins and neutral protamine Hagedorn (NPH) insulin to more-expensive rapid-acting insulin analogues and long-acting insulin analogues. Short-acting insulin analogues provide a more rapid onset of action than regular human insulin and long-acting insulin analogues require fewer injections than NPH insulin.

The new Pharmacor report entitled Type 1 Diabetes finds that market growth will be driven by rapid-acting insulin analogues that include Novo Nordisk's Novorapid/Novolog and Eli Lilly's Humalog as well as long-acting insulin analogues that include Sanofi-Aventis's Lantus and Novo Nordisk's Levemir. Since the type 1 diabetes market is saturated with effective and well-established insulin-based therapies that have been in use for decades, the report forecasts only modest 1.2 percent annual market growth through 2017.

According to the report, novel devices designed to allow needle-free administration of insulin could revolutionize treatment of type 1 diabetes, but their uptake will be hampered by physicians' negative experience with Pfizer/Nektar's inhaled insulin, Exubera, which fared poorly in the market owing to safety concerns and its premium price. Among the insulin-based therapies currently in the pipeline for type 1 diabetes, oral and transdermal insulins hold the greatest promise but their use will be constrained by dosing variability issues that are likely to dissuade physicians from prescribing them.

The report also finds that novel immu
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
2. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
3. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
4. Treatment Corrects Severe Insulin Imbalance in Animal Studies
5. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
6. Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
7. Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
8. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
9. Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
10. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
11. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Solutions LLC today announced the launch of their ... a minimally invasive, Board Certified, OB/GYN surgeon Dr. ... improve patient and surgical team safety.  This proprietary device ... and reload sutures with an efficient, one-handed motion resulting ...
... (Nasdaq: BMRN ) announced today that the ... study (PKU-016) to evaluate the effects of Kuvan (sapropterin ...  BioMarin expects to report results in the first half ... will provide quantitative data regarding the neuropsychiatric effects of ...
Cached Medicine Technology:Equinox Surgical Solutions Launches Flagship Product, SutureAssist® 2BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU 2BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU 3
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... Calif.) An international team led by researchers at ... complex, which plays a key role in cell division, ... This is the first time the complex has been ... make cyclin B1/Cdk1 an excellent target to control cellular ... The research was published online today in the journal ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... (Providence, RI)--- EpiVax, Inc, a leader in the field ... funding from the Juvenile Diabetes Research Foundation (JDRF), the ... to develop Epi-13, a novel therapeutic for the prevention ... chronic autoimmune disease that affects up to three million ...
... 2007 - Diseases that cause neurons to break-down, ... (Mad Cow Disease), continue to be elusive to ... from University of Michigan researchers demonstrates an unpredicted ... neuron health., In a study released in PNAS, ...
... ElBaradei will join more than 100 leading public figures, ... in New York on 29 October to mark the ... the US based National Foundation for Cancer Research (NFCR). ... PACT Fund at NFCR, Americans can support the IAEA ...
... is generally considered to be safe with a low ... tube can lead to serious complications. , The ... Dr. Imamura of Aichi Medical University Hospital. It was ... Gastroenterology. , An 86-year-old woman with gastrostomy tube feeding ...
... ALTO, Calif., Oct. 25 ASTRO Booth # ... today announced that it has developed,groundbreaking technology for ... of volumetric arc therapy. Varian,s new RapidArc(TM),radiotherapy technology* ... to deliver more precise forms of intensity-modulated radiation,therapy ...
... Coley,Pharmaceutical Group, Inc. (Nasdaq: COLY ), today announced ... 4:30 p.m. Eastern Time on November,1, 2007 to discuss ... live audio broadcast or the subsequent archived recording,of the ... Coley website,at http://www.coleypharma.com . Please log onto Coley,s ...
Cached Medicine News:Health News:EpiVax receives JDRF program funding to develop diabetes drug using natural 'regulatory' T-cells 2Health News:U-M scientists find new causes for neurodegeneration 2Health News:IAEA and NFCR join forces to fight cancer in developing world 2Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 2Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 3Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 4Health News:Coley Pharmaceutical Group to Report Third Quarter Results on November 1, 2007 2
Curved shafts with fine pointed tips. Smooth handle with dull finish....
Delicate curved shafts with light crisscross serrations. Serrated handle with polished finish. Most popular size or model....
Delicate cross serrated lightly curved tips with serrated handle and polished finish. Most popular size or model....
Delicate lightly curved tips, 1 x 2 mouse style teeth. Serrated handle with polished finish....
Medicine Products: